Beyond the lungs: the hidden emotional toll of IPF medications

NCT ID NCT07743996

Recruiting now Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Aug 04, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This study uses an online questionnaire to understand how side effects from antifibrotic medications affect the emotional and social well-being of patients with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF) in Japan. Researchers will ask about patients' experiences and satisfaction with their medications, focusing on the burden of side effects. The goal is to see how these experiences relate to patients' individual characteristics, which could help improve support for those undergoing treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: No intervention; this is an observational survey study
What this could lead to: If successful, this could help doctors better understand and support the emotional and social challenges patients face from antifibrotic treatment side effects.
What could go wrong: This is a small, survey-based study in Japan, so results may not apply to other populations or settings. It does not test a treatment, so it cannot change outcomes directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS PROGRESSIVE PULMONARY FIBROSIS

Contacts and locations

Locations

Nippon Boehringer Ingelheim Co., Ltd.
RECRUITING

Tokyo, 141-6017, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.